Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Pinnacle Biologics Inc. Stories

2014-03-26 08:28:35

Supplemental approval will expand PDT with Photofrin® treatments in specific lung and esophageal cancers TORONTO AND BANNOCKBURN, IL, March 26, 2014 /PRNewswire/ - Concordia Healthcare Corp. (Concordia or the Company) (TSX:CXR) (OTCQX: CHEHF) announced today that its subsidiary Pinnacle Biologics, Inc. (Pinnacle), a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration (FDA) premarket supplemental...

2013-12-24 08:24:11

TSX: CXR Newly listed company's purchase adds new products and increases R&D strength TORONTO, ON AND BANNOCKBURN, IL, Dec. 24, 2013 /PRNewswire/ - Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs, announced today that it has acquired Pinnacle Biologics, Inc., a U.S.-based biopharmaceutical company specializing in...

2012-12-05 08:25:42

BANNOCKBURN, Ill., Dec. 5, 2012 /PRNewswire/ -- Pinnacle Biologics, Inc., a bio-pharmaceutical technology company developing and manufacturing novel therapies for oncology and rare diseases announced today the acquisition of laser technologies for use in photodynamic therapy (PDT). The acquisition includes the Diomed(TM) PDT 630 laser and the OPTIGUIDE(TM) fiber optic diffusers, which are currently the only FDA-approved devices for use in PDT with PHOTOFRIN ® (porfimer sodium) for...

2012-06-26 10:24:18

BANNOCKBURN, Ill., June 26, 2012 /PRNewswire/ -- Pinnacle Biologics, Inc., a bio-pharmaceutical technology company developing and manufacturing novel therapies for oncology and rare diseases and European-based INTERmedic, a medical laser and light technology company, announced a global manufacturing and distribution agreement of INTERmedic's latest photodynamic therapy (PDT) laser for exclusive use with Pinnacle's PHOTOFRIN ® (porfimer sodium) for injection. PDT is a two-step...

2012-06-04 14:22:58

BANNOCKBURN, Ill., June 4, 2012 /PRNewswire/ -- Pinnacle Biologics, Inc. announced that the Board of Directors has elected Robert S. Altman, Ph.D. as Chief Commercial Officer, effective today. Mr. Altman is a proven leader with over 20 years experience in pharmaceutical industry. He was most recently CEO and President of Marathon Pharmaceuticals, LLC. From 2004 to 2007 Bob served as Senior Vice President Marketing and Sales of Astellas Pharma US. Previously Mr. Altman worked...

2012-01-09 17:11:00

BANNOCKBURN, Ill., Jan. 9, 2012 /PRNewswire/ -- Led by NUMODA CAPITAL INNOVATIONS, LLC., PINNACLE BIOLOGICS announced today the succesful completion of a financing round, in a combination of Equity, and Debt Conversion. "Today's announcement represents another major milestone for Pinnacle Biologics. After completing the acquisition of the Global Photo Dynamic Therapy ("PDT") Business from Aptalis Pharma early last year, Pinnacle continues the process of solidifying its presence in the US...

2011-12-14 09:35:00

BANNOCKBURN, Ill., Dec. 14, 2011 /PRNewswire/ -- Pinnacle Biologics, Inc., a privately held specialty bio-pharmaceutical company announced today that it has obtained approval for an Orphan Drug Designation (ODD) for their product PHOTOFRIN® (porfimer sodium) as adjuvant therapy to surgery in the treatment of malignant pleural mesothelioma. Malignant pleural mesothelioma is a form of cancer affecting the lining of the lungs. It is a rare, highly aggressive and...

2011-10-24 14:57:00

BANNOCKBURN, Ill., Oct. 24, 2011 /PRNewswire/ -- Pinnacle Biologics, Inc., a privately held specialty bio-pharmaceutical company announced today that it has filed an Orphan Drug Designation (ODD) for their product PHOTOFRIN® (porfimer sodium) as adjuvant therapy to surgery in the treatment of Malignant Pleural Mesothelioma. Malignant Pleural Mesothelioma is a form of cancer affecting the lining of the lungs. It is a rare, highly aggressive and devastating cancer with a...

2011-09-19 14:05:00

BANNOCKBURN, Ill., Sept. 19, 2011 /PRNewswire/ -- Effective October 1 2011, Pinnacle Biologics Inc., grants exclusive distribution rights for PHOTOFRIN® and PHOTOBARR® to ALKOPHARMA SA for most of European countries, Middle East and most South East Asian Countries. "We are pleased to expand our strategic partnership with members of the ALKOGROUP companies, ALKOPHARMA and GENOPHARM, through the addition of a second product and expanded territories to our...

2011-06-27 10:00:00

BANNOCKBURN, Ill., June 27, 2011 /PRNewswire/ -- Pinnacle Oncology LLC, a subsidiary of Pinnacle Biologics Inc. announced a wide ranging agreement with the University of Chicago for the acquisition of its technology and intellectual property rights for the development of a compound, amifostine, to prevent genomic instability caused by a variety of sources of ionizing radiation exposure including common Computer Tomography (CT) scans. Amifostine was initially developed by the United...